Martin Pomper

Foley & Lardner LLP engages in the provision of legal services. Its practice areas include employee benefits and executive compensation, environmental, estates and trusts, finance, international tax and transfer pricing, private equity and venture capital, real estate, securities, commodities and exchange regulation, taxation, and transactions. The company was founded by Asahel Finch and William Pitt Lynde on September 8, 1842 and is headquartered in Milwaukee, WI.

Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.

2020, Inc. offers eye care services. It also offers delivers on-site eye care and eye exams to businesses and their employees via a mobile eye clinic. The company was founded by Howard Bornstein in 2013 and is headquartered in Boston, MA.

Pinteon Therapeutics, Inc. develops cancer and CNS therapeutics. It focuses on the discovery and development of therapeutics targeting Pin1. The firm specializes in aberrant disease processes and improves patient outcomes in medical need indications. The company is headquartered in Newton Centre, MA.

Procter & Gamble Ltd. manufactures and markets consumer products. It provides fabric and home care products which include laundry, cleaning, detergents, soaps, softeners, and cleansers. The company was founded in 1837 and is located in Newcastle, UK.

Morningside Group (Morningside Group) is a venture capital and private equity firm founded in 1986 by Lok Chung Chan and Chi Chung Chan. The firm is headquartered in Hong Kong.

CellFactors Plc develops therapeutic products derived from human cells. The private company is based in Babraham, UK.

CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

John Innes Centre Ltd. provides research services in plant science and microbiology. It carries out fundamental research to train scientists and make their findings available to society. The scientific research at the center makes use of a range of disciplines in the biological and chemical sciences, including cell biology, biochemistry, genetics, molecular biology, computational and mathematical biology. The company was founded in 1910 and is headquartered in Norwich, the United Kingdom.

GreenLight Biosciences, Inc. engages in a biotechnology company.. It delivers attractive solution for production of chemicals and fuels from renewable resources, eliminating the need for petroleum feedstocks. The company was founded by Andrey J. Zarur, Marta Ortega-Valle, and James R. Swartz and is headquartered in Medford, MA.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

PlaqueTec Ltd. develops a liquid biopsy system platform technology that provides unparalleled resolution of the biological processes that cause coronary artery disease. The firm’s Liquid Biopsy System addresses the underlying biomarker collection problems preventing advances in CAD research. The company was founded by Stephen Blatcher in 2000 and is headquartered in Cambridge, the United Kingdom.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Galileo CDS, Inc. provides integrated diagnostic decision support and report generation services. The company was founded by R. Nick Bryan and Edward Herkovits and is headquartered in Philadelphia, PA.

Alms Therapeutics SAS provides research and development in the treatment of diabetes. The company was founded by Jason Robert Dinges on July 4, 2017 and is headquartered in Paris, France.

Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA.

Allysta Pharmaceuticals, Inc. operates as a biopharmaceutical company. The frim develops medicine for ophthalmology, particularly dry eye disease and glaucoma. The company was founded by Henry H. Hsu and is headquartered in San Mateo, CA.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands.

Cyted Ltd. provides digital diagnostic infrastructure to know the early detection of cancer. The company was founded by Marcel Gehrung, Rebecca Fitzgerald, and Maria O'Donovan and is headquartered in Cambridge, the United Kingdom.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.

Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.